CAMPfield Therapeutics Raises $180M Series A to Advance Oral PDE4 Inhibitor for IBD

Why It Matters

With over a dozen IBD therapies yet many patients failing to achieve durable remission, prifemilast could offer a once‑daily oral option that improves efficacy and tolerability, reshaping the treatment landscape.

Key Takeaways

• cAMPfield raised $180M Series A for IBD drug development
• Prifemilast is a selective PDE4B oral inhibitor
• Over 700 patients have already taken prifemilast in trials
• Phase 2b ulcerative colitis trial slated globally this year
• Founders bring experience from Entyvio, Otezla, Zeposia

Pulse Analysis

Inflammatory bowel disease remains a high‑unmet‑need market despite more than a dozen approved biologics and small molecules. Patients often cycle through therapies due to limited durability, safety concerns, or the inconvenience of injectables. Oral agents that can deliver consistent disease control are especially attractive, and PDE4 inhibition has emerged as a promising mechanism, given its role in modulating key inflammatory pathways.

cAMPfield Therapeutics entered the arena with a robust $180 million Series A, led by Frazier Life Sciences and backed by Deep Track, Forbion, and other heavyweight investors. The company secured exclusive global rights—outside Greater China—to prifemilast from Newsoara Biopharma, a deal that builds on a prior $135 million licensing arrangement with vTv Therapeutics. The founding team, featuring former Takeda gastroenterology head Asit Parikh and ex‑Celgene/BMS executives, brings deep experience from successful IBD launches such as Entyvio, Otezla, and Zeposia, lending credibility to the venture’s ambitious development plan.

Looking ahead, cAMPfield plans to initiate a global Phase 2b trial in moderate‑to‑severe ulcerative colitis and a parallel Phase 2 study for Crohn’s disease, leveraging data from over 700 trial participants that indicate a favorable safety profile and comparable discontinuation rates to placebo. If the upcoming trials confirm efficacy, prifemilast could differentiate itself by offering once‑daily oral dosing with reduced PDE4D‑related side effects, positioning it as a best‑in‑class candidate. Success would not only expand therapeutic options for patients but also intensify competition among oral IBD agents, potentially driving innovation and pricing dynamics across the sector.

Deal Summary

cAMPfield Therapeutics announced a $180 million Series A financing round led by Frazier Life Sciences, with participation from Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings and RA Capital. The capital will fund development of its licensed oral PDE4 inhibitor prifemilast for inflammatory bowel disease. The round was disclosed on June 18, 2026.